We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+147.5%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$163M
AUM Growth
–
Cap. Flow
+$115M
Cap. Flow %
70.22%
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$52M
2
THOR
Synthorx, Inc. Common Stock
THOR
+$28.7M
3
MRUS
Merus
MRUS
+$25.7M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$8.16M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THOR
1
DELISTED
Synthorx, Inc. Common Stock
THOR
$70.3M 43.05%
+1,005,184
New +$28.7M
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$64.4M 39.46%
+2,067,861
New +$52M
MRUS
3
DELISTED
Merus
MRUS
$22.5M 13.81%
+1,600,000
New +$25.7M
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6M 3.68%
+1,570,000
New +$8.16M

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Medicxi Ventures Management, which disclosed 4 positions worth $163M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Phathom Pharmaceuticals: 2,067,861 shares worth $64.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Medicxi Ventures Management's largest Q4 2019 buy was Phathom Pharmaceuticals: 2,067,861 shares worth $64.4M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $163M portfolio in Q4 2019.
  • Medicxi Ventures Management disclosed 4 positions in Q4 2019, its first 13F filing on record.

Based on Medicxi Ventures Management's 13F filing for Q4 2019, filed 11 Feb 2020.